ClinicalTrials.gg
RecruitingNCT06951646Updated Mar 9, 2026

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

A Phase 2 interventional study of Ivonescimab and Docetaxel in Non Small Cell Lung Cancer and Immune Checkpoint Inhibitors (ICIs), sponsored by Second Xiangya Hospital of Central South University. Recruiting at 20 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Second Xiangya Hospital of Central South University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung — 23 open to participants now, 30 under way, 7 of them phase 3. ivonescimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
16th of 31
70 · median 70
Started
2026
with 15 others
Phase 2
17 of 31
16 open now
Primary completion
2028-07
later than 23 of 29 live
Registered
13th of 31
by date

Among the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by planned enrollment, is one of 16 that started in 2026, is one of 17 in phase 2, reaches primary completion later than 23 of the 29 other live ones, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

23 of the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About ivonescimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The CR1STAL-Adaptive study is a randomized, open-label, phase II multicenter interventional trial designed to evaluate the safety and efficacy of Ivonescimab (PD-1/VEGF bispecific antibody) combined with docetaxel versus standard treatment in patients with advanced NSCLC who have achieved long-term benefit from first-line immune checkpoint inhibitors (ICIs), but are ctDNA-MRD positive. Building upon insights from previous CR1STAL study (NCT05198154), the CR1STAL-Adaptive study supports the development of precision-guided, adaptive treatment strategies to delay progression and improve outcomes in NSCLC patients with a long-term response to immunotherapy. It represents a step forward in integrating dynamic molecular monitoring with individualized intervention strategies in the era of immunotherapy.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Immune Checkpoint Inhibitors (ICIs)

Keywords

  • Non Small Cell Lung Cancer (NSCLC)
  • Immune Checkpoint Inhibitors (ICIs)
  • Circulating-tumor DNA (ctDNA)
  • Minimal Residual Disease (MRD)
  • Ivonescimab (AK112)
  • Adaptive Therapy
  • Bispecific Antibody
  • Escalation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign written prior to any study-related procedures, be willing and able to complete the visits, treatment regimen, and laboratory tests specified in the schedule, and comply with other requirements of the study;
  2. Aged ≥18 and ≤75 years old;
  3. PS score 0-1;
  4. Expected survival time ≥ 12 weeks;
  5. Patients with stage IIIB-IIIC and IV non-small cell lung cancer confirmed by histology or cytology that cannot be treated locally (TNM lung cancer staging of the 9th edition of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification);
  6. There must be no EGFR gene-sensitive mutation, ALK gene fusion or ROS1 gene fusion in non-squamous carcinoma
  7. Immunotherapy combined with platinum-containing doublet chemotherapy as a standard treatment regimen;
  8. Non-PD with PFS at screening enrollment is 11 to 15 months;
  9. According to the (RECIST version 1.1), it is recommended to have at least one , but patients without measurable lesions can still be included in the group (primary tumor recurrence or new lesions are considered PD).

Participants with who are asymptomatic or whose symptoms are stable after local treatment are allowed to enroll, as long as the participants meet the following conditions:

  1. There are measurable lesions outside the central nervous system
  2. No central nervous system symptoms or no worsening of symptoms for at least 2 weeks
  3. No need for treatment, or glucocorticoid treatment was discontinued within 7 days before the first dose, or the glucocorticoid dosage was stable and reduced to less than 10mg/day prednisone (or equivalent dose) within 7 days before the first dose.

10. Meet the following laboratory indicators (within 14 days before the first treatment):

  1. Routine blood test: ≥1.5×109/L; count ≥100×109/L; content ≥9.0 g/dL (no blood transfusion or erythropoietin-dependent administration within 7 days).
  2. Liver function: total (TBIL) ≤1.5× (ULN); for patients with liver metastasis or confirmed/suspected Gilbert's syndrome, TBIL ≤3×ULN; in the absence of liver metastasis, (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN. For patients with liver metastasis, ALT or AST ≤5×ULN.
  3. Renal function: serum creatinine (Cr) ≤ 1.5 times ULN or Cr clearance ≥ 50 mL/min ( formula), and urine routine test results show urine protein (UPRO) \<2+ or 24-hour urine protein quantification \<1g.
  4. Coagulation function: (INR) ≤ 1.5 times ULN or partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; if the study participants are receiving anticoagulant therapy, as long as PT is within the range of the anticoagulant drug;
  5. Cardiac function: (LVEF) ≥ 50% 11. For female study participants of childbearing age, a urine or serum pregnancy test with a negative result should be performed within 3 days before the first dose of study drug (Day 1 of Cycle 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non-childbearing age are defined as women who have been for at least 1 year, or have undergone surgical sterilization or hysterectomy; if there is a risk of pregnancy, all study participants (whether male or female) must use measures with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last dose of study drug (or 180 days after the last dose of study drug).

12. If an intact male study participant has sexual intercourse with a female partner of , the study participant must use effective contraception from screening until day 120 after the last dose. Whether to discontinue contraception after this time point should be discussed with the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent participation in another interventional clinical study or receipt of another drug, unless participating in an observational clinical study;
  2. Systemic therapy with proprietary Chinese medicines with anti-tumor indications or immunomodulatory drugs (including thiopeptides, interferons, interleukins, except those used locally for the control of hydrothorax or ascites) within 2 weeks prior to the first dose;
  3. No as defined by 1.1 due to prior radical treatment (e.g., surgery or radiotherapy)
  4. Subjects who have received systemic antiangiogenic therapy;
  5. Subjects who are enrolled in another clinical study at the same time, unless it is a non-interventional clinical study or the follow-up period of an interventional study (defined as the time between the first dose of this study and the last dose of the previous clinical study being more than 4 weeks or more than 5 half-lives of other study drugs, whichever is shorter);
  6. During the screening period, imaging shows that the tumor surrounds important blood vessels or there is significant necrosis or cavity, and the investigator determines that entering the study will cause a risk of bleeding;
  7. Imaging findings during the screening period show that the tumor invades important peripheral organs and blood vessels (such as the heart and pericardium, trachea, esophagus, aorta, superior vena cava, etc.) or there is a risk of developing esophagotracheal fistula or esophagopleural fistula;
  8. Active diseases requiring systemic treatment (such as treatment with disease-modifying drugs, , and ) within 2 years before the first dose (excluding irAEs caused by the use of /L1 inhibitors). Replacement therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a systemic treatment;
  9. A history of major diseases within 1 year before the first dose, specifically:

    • Unstable angina, myocardial infarction, congestive heart failure ( classification ≥ Class 2) or vascular diseases (such as aortic aneurysm with a risk of rupture) that require hospitalization within 12 months before the first dose, or other cardiac damage that may affect the safety evaluation of the study drug (such as poorly controlled arrhythmia, myocardial ischemia, etc.);
    • Hepatic encephalopathy, hepatorenal syndrome or class B or more severe cirrhosis
    • Current hypertension with systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg after oral antihypertensive therapy;
    • Hyperglycemia that cannot be controlled after treatment (fasting blood glucose > 10 mmol/L);
    • A history of esophageal and gastric varices, with severe ulcers and unresolved wounds, abdominal fistulas, intraabdominal abscesses, or acute gastrointestinal bleeding within 6 months before the first dose;
    • Any arterial thromboembolic events, venous thromboembolic events of grade 3 orabove as specified in 5.0, , cerebrovascular accidents, hypertensive crises, or hypertensive encephalopathy that occurred within 6 months before the first dose;
    • Acute exacerbation of that occurred within 4 weeks before the first dose;
    • Active or prior history of inflammatory bowel disease (such as Crohn's disease, ulcerative colitis, or chronic diarrhea);
  10. A history of gastrointestinal perforation and/or fistula, a history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), or extensive bowel resection (partial colon resection or extensive small bowel resection, with chronic diarrhea) within 6 months before the first dose;
  11. Those who have received chest radiotherapy >30 Gy within 6 months before the first dose, non-chest radiotherapy >30 Gy within 4 weeks before the first dose, and palliative radiotherapy ≤ 30 Gy within 2 weeks before the first dose, and who have not recoveredfrom the toxicity and/or complications of these interventions to NCI-CTC AE ≤ grade 1 (excluding alopecia and fatigue). Palliative radiotherapy to control symptoms is allowed, but it must be completed at least 2 weeks before the first dose, and no additional radiotherapy is scheduled for the same lesion;
  12. Those who have received live or within 4 weeks before the first dose, or plan to receive live or live attenuated vaccines during the study period. The use of inactivated vaccines is allowed;
  13. Severe infections within 4 weeks before the first dose, including but not limited to complications requiring hospitalization such as sepsis, or severe pneumonia; active infections that have received systemic anti-infective treatment within 2 weeks before the first dose (excluding antiviral treatment for or C);
  14. Those with a history of severe bleeding tendencies or coagulation disorders; those with bleeding symptoms within 4 weeks before the first dose, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or vomiting up ≥ 1 teaspoon of blood or small blood clots, or only coughing up blood without sputum; those with blood in the sputum are allowed to be enrolled), nasal bleeding (excluding epistaxis and bloody nasal discharge); those who have received continuous antiplatelet or anticoagulant therapy (except for preventive use of anticoagulants, such as the use of anticoagulants to maintain venous patency) within 14 days before the first dose;
  15. Those who have undergone major surgery or experienced severe trauma within 4 weeks before the first dose, or have a major surgery planned within 4 weeks after the first dose (as determined by the investigator);
  16. Presence of clinically uncontrolled pleural effusion or ascites (subjects may be recruited who do not require drainage of the effusion or who do not have a significant increase in the effusion after 3 days of cessation of drainage)
  17. Previous history of non-infectious pneumonia requiring systemic glucocorticoid treatment or current interstitial lung disease;
  18. Those with a history of immunodeficiency; those with positive antibody tests;
  19. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation;
  20. Subjects with untreated active hepatitis B (HBsAg positive and HBV-DNA > 1000 copies/mL (200 IU/mL) or above the lower limit of detection, whichever is higher), for subjects with hepatitis B who are required to receive anti-hepatitis B virus treatment during the study treatment period; subjects with active subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection);
  21. Known presence of active pulmonary tuberculosis (TB);
  22. Known active syphilis infection;
  23. Known allergy to any component of any study drug; a known history of severe to other monoclonal antibodies
  24. Those with a history of immunodeficienc; those who are currently receiving long-term systemic corticosteroids or other immunosuppressants;
  25. A known history of mental illness, drug abuse, alcohol or drug addiction;
  26. The toxicity of previous anti-tumor therapy has not been relieved, which is defined as the toxicity has not returned to grade 1 or below specified in NCI CTCAE 5.0, or the level specified in the inclusion/exclusion criteria, except for alopecia and fatigue;
  27. Known symptomatic and/or carcinomatous meningitis. Subjects with previously treated brain metastases may be enrolled in the trial if they are clinically stable (no evidence of imaging progression for at least 4 weeks prior to the first dose of the experimental treatment, no evidence of new brain metastases or increase in size of pre-existing brain metastases as confirmed by repeat imaging) and do not require steroid therapy for at least 14 days prior to the first dose of the experimental treatment. This exception does not include carcinomatous meningitis, which should be excluded regardless of whether it is clinically stable.
  28. History of other primary within 5 years, except:

    • malignancies that have been in complete remission for at least 2 years prior to enrolment and for which no other treatment was required during the study period.
    • adequately treated non-melanoma skin cancer or malignant nevus with no evidence of disease recurrence.
    • adequately treated carcinoma in situ without evidence of disease recurrence
  29. Subjects who are pregnant or breastfeeding or plan to breastfeed during the study;
  30. Other acute or chronic illnesses, psychiatric disorders, or abnormal laboratory test values that could increase the risks associated with study participation or study drug administration or interfere with the interpretation of study results and, in the investigator's judgment, render the patient ineligible for participation in the study.
  31. Uncontrolled metabolic disorders, or local or systemic diseases due to non-malignant tumors, or diseases or symptoms secondary to the tumor, which may lead to higher medical risk and/or uncertainty in survival assessment, or diseases that the investigator considers unsuitable for enrollment;
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Other
    Standard Treatment

    For ctDNA-positive patients, the original maintenance treatment (eg. immunotherapy or immunotherapy combined with chemotherapy) will be continued.

    Other: Standard Treatment group

  • Experimental
    Escalation Treatment

    For ctDNA-positive patients, escalation treatment will be administrated

    Drug: Ivonescimab · Drug: Docetaxel

Interventions

  • For ctDNA-positive patients, escalation treatment will be administrated Ivonescimab: Intravenous infusion (IV), 20 mg/kg, Day 1, every 3 weeks (Q3W); All enrolled participants will continue treatment until one of the following occurs, whichever comes first: * The investigator determines that there is no longer clinical benefit (based on imaging assessments and clinical status) * Unacceptable toxicity * Completion of 24 months of treatment * Other discontinuation criteria specified in the protocol are met.

  • For ctDNA-positive patients, escalation treatment will be administrated Docetaxel: IV, 75 mg/m², Day 1, Q3W (The investigator may adjust the chemotherapy dose and schedule based on the patient's tolerance during treatment.) All enrolled participants will continue treatment until one of the following occurs, whichever comes first: * The investigator determines that there is no longer clinical benefit (based on imaging assessments and clinical status) * Unacceptable toxicity * Completion of 24 months of treatment * Other discontinuation criteria specified in the protocol are met.

    Also known as: AK112

  • OtherStandard Treatment group

    For ctDNA-positive patients, continuing the original immunotherapy maintenance or immunotherapy combined with chemotherapy

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) in ctDNA-Positive Population

    The duration from randomization to disease progression or death (whichever occurs first), as assessed by the investigator based on RECIST v1.1 criteria.

    Time frame: 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the duration from randomization to death due to any cause.

    Time frame: 5 years

  2. Adverse Event

    The incidence of adverse events (AEs) will be evaluated according to CTCAE version 5.0. A detailed description of AEs, as well as laboratory data and vital signs, will be provided. The number of patients who experience at least one adverse event will be calculated.

    Time frame: AEs must be collected from the start of treatment to 28days after discontinuation of study drug, up to 24months

  3. 18-Month PFS Rate

    This is defined as the proportion of patients who have not experienced disease progression or death from randomization until 18 months, as assessed by the investigator according to RECIST v1.1 criteria.

    Time frame: 3 years

  4. ctDNA Clearance Rate

    The clearance rate of ctDNA at C3D1 after escalated treatment.

    Time frame: 3 years

  5. Objective Response Rate (ORR)

    Defined as the proportion of study participants achieving a Complete Response (CR) or Partial Response (PR) among all study participants.

    Time frame: 3 years

  6. Disease Control Rate (DCR)

    DCR is defined as the proportion of study participants achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) among all study participants.

    Time frame: 3 years

  7. Duration of Response (DoR)

    Defined as the length of time from the first achievement of an objective response (CR or PR) to disease progression or death.

    Time frame: 3 years

  8. Quality of Life (QoL)

    Quality of life (QoL) is assessed longitude by EORTC QLQ-C30 (version.3). The EORTC QLQ-C30 is composed of 9 multi-item scales: 5 functioning scales (physical, role, cognitive, emotional, and social), a global QOL scale, and 3 symptom scales (fatigue, pain, and nausea/vomiting). All scales and single items are linearly transformed to an 0-100 scale. A higher score represents a better level of functioning.

    Time frame: 3 years

  9. Progression-Free Survival (PFS) in the ctDNA-negative Arm

    In the ctDNA-negative population, the duration from study enrollment to disease progression or death (whichever occurs first), as assessed by the investigator based on RECIST v1.1 criteria.

    Time frame: 3 years

  10. Overall Survival (OS) in the ctDNA-negative Arm

    In the ctDNA-negative population, the duration from study enrollment to death due to any cause.

    Time frame: 3 years

Other outcomes

  1. The correlation between biomarkers and efficacy prediction

    Including but not limited to PD-L1 expression levels in tumor tissue samples, genetic signatures, immune cell infiltration (T cells, B cells, macrophages, etc.), peripheral blood markers (methylation modifications, RNA levels and modifications, protein modifications), blood immune cell composition (TCR, BCR, etc.), blood metabolites (carbohydrates, lipids, amino acids, etc.), and gut microbiota composition.

    Time frame: 3 years

  2. Exploration of Multiparametric Imaging Biomarkers Predictive of Efficacy

    Including but not limited to imaging data from CT, MRI, and PET-CT.

    Time frame: 3 years

07

Study locations

1 of 20 sites recruiting
  • Hunan Cancer Hospital
    Changsha, 410011, China
    Not yet recruiting
    • Xingxiang Pu · Contact
  • The Second Xiangya Hospital of Central South University
    Changsha, 410011, China
    Recruiting
    • Fang Wu · Contact
  • The Third Hospital of Changsha
    Changsha, 410011, China
    Not yet recruiting
    • Zengmei Sheng · Contact
  • Xiangya Hospital of Central South University
    Changsha, 410011, China
    Not yet recruiting
    • Min Li · Contact
  • Changsha Central Hospital
    Changsha, China
    Not yet recruiting
    • Qin Chai · Contact
  • The First Hospital of Changsha
    Changsha, China
    Not yet recruiting
    • Ping Liu · Contact
  • The Third Xiangya Hospital of Central South University
    Changsha, China
    Not yet recruiting
    • Yan Zhou · Contact
  • Army Medical Center (Daping Hospital)
    Chongqing, China
    Not yet recruiting
    • Li Li · Contact
  • Guiyang Public Health Clinical Center
    Guiyang, China
    Not yet recruiting
    • Yong Hu · Contact
  • Faculty of Medicine, The Chinese University of Hong Kong
    Hong Kong, China
    Not yet recruiting
    • Molly Li · Contact
  • Kiang Wu Hospital, Macao
    Macao, China
    Not yet recruiting
    • Yabing Cao · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
    Not yet recruiting
    • Longhua Sun · Contact
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, China
    Not yet recruiting
    • Qing Bu · Contact
  • Liaoning Cancer Hospital and Institute
    Shenyang, China
    Not yet recruiting
    • Yuan Liang · Contact
  • Shanxi Bethune Hospital
    Taiyuan, China
    Not yet recruiting
    • Huijing Feng · Contact
  • Hubei Cancer Hospital
    Wuhan, China
    Not yet recruiting
    • Bin Yang · Contact
  • Renmin Hospital of Wuhan University
    Wuhan, China
    Not yet recruiting
    • Bicheng Zhang · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
    Not yet recruiting
    • Rui Meng · Contact
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, China
    Not yet recruiting
    • Yinghua Ji · Contact
  • Zhuzhou Central Hospital
    Zhuzhou, China
    Not yet recruiting
    • Min Liu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jul 2028, 27 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 27 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
Apr 30, 2025
StartEst.
Mar 10, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jun 1, 2030
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06951646
Lead sponsor
Second Xiangya Hospital of Central South University
Collaborators
Nanjing Shihejiyin Technology, Inc., Akeso
Responsible party
Fang Wu (Professor, Second Xiangya Hospital of Central South University) — Principal investigator
First posted
Apr 30, 2025
Start date
Mar 10, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Mar 9, 2026

Study contacts

Fang Wu, MD, PhD
Contact
wufang4461@edu.csu.cn
+86 13574858332

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivonescimab · Docetaxel

Start the discussion